(0.31%) 5 115.88 points
(0.30%) 38 355 points
(0.35%) 15 984 points
(-1.00%) $83.01
(5.25%) $2.02
(0.30%) $2 354.30
(0.36%) $27.63
(4.11%) $960.00
(-0.27%) $0.932
(-0.45%) $10.98
(-0.58%) $0.796
(1.66%) $93.40
@ $8.45
発行日: 14 2月 2024 @ 23:30
リターン: 7.93%
前回のシグナル: 2月 14 - 03:42
前回のシグナル:
リターン: 1.38 %
Live Chart Being Loaded With Signals
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia...
Stats | |
---|---|
本日の出来高 | 84 898.00 |
平均出来高 | 372 882 |
時価総額 | 439.26M |
EPS | $0 ( 2024-02-26 ) |
次の収益日 | ( $-0.190 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.12 |
ATR14 | $0.0100 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Winningham Rick E | Buy | 300 000 | Ordinary Shares |
2024-04-02 | Sawaf Aziz | Buy | 100 000 | Ordinary Shares |
2024-04-02 | Miller Aine | Buy | 37 500 | Ordinary Shares |
2024-04-02 | Grimaud Brett A. | Buy | 100 000 | Ordinary Shares |
2024-04-02 | Farnum Rhonda | Buy | 37 500 | Ordinary Shares |
INSIDER POWER |
---|
46.99 |
Last 95 transactions |
Buy: 1 532 401 | Sell: 647 888 |
ボリューム 相関
Theravance Biopharma Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Theravance Biopharma Inc 相関 - 通貨/商品
Theravance Biopharma Inc 財務諸表
Annual | 2023 |
収益: | $57.42M |
総利益: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2023 |
収益: | $57.42M |
総利益: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2022 |
収益: | $51.35M |
総利益: | $44.76M (87.17 %) |
EPS: | $-1.260 |
FY | 2021 |
収益: | $55.31M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。